Story perspectives

GSK to acquire Chimagen’s trispecific T-cell engager rights

By Drooid · Sep 16, 2026, 6:45 AM UTC · How we work

Summary

Story summary

GSK agreed to acquire rights to Chimagen’s trispecific T-cell engager for up to $750 million.
The candidate will begin Phase I trials in 2027 targeting multiple myeloma.
Chimagen claims the therapy seeks deeper, more durable responses with better tolerability than existing TCEs.
GSK projects the U.S. multiple-myeloma T-cell engager market could exceed $10 billion by 2032.

History

Historical Context

The first FDA-approved CAR-T therapy, Novartis’ Kymriah, received clearance in August 2017 after Carl H. June’s University of Pennsylvania team demonstrated its efficacy, marking the transition from early-generation CARs to clinically proven immunotherapy. By 2024, GSK’s $750 million acquisition of Chimagen’s trispecific T-cell engager reflects the field’s evolution toward multi-antigen approaches, a shift underscored by roughly 364 global CAR-T trials.

1 of 2

Story summary

GSK agreed to acquire rights to Chimagen’s trispecific T-cell engager for up to $750 million.
The candidate will begin Phase I trials in 2027 targeting multiple myeloma.
Chimagen claims the therapy seeks deeper, more durable responses with better tolerability than existing TCEs.
GSK projects the U.S. multiple-myeloma T-cell engager market could exceed $10 billion by 2032.

1 / 2